YOU ARE HERE: Home > Guidelines and Clinical Policy > 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation ...

People who reported spending six or more hours on screens outside of school or work had worse blood pressure, cholesterol and body mass index (BMI) compared with those with more limited screen time, ...

The newest clinical guideline released by the ACC and the American Heart Association (AHA) provides new and updated recommendations for preventing and optimally managing atrial fibrillation (AFib).

In the H-HeFT trial, conducted at multiple centers in Denmark as part of the broader DANHEART study, 592 patients were randomized to twice-daily hydralazine 37.5 mg plus isosorbide dinitrate 20 mg ...

Among community-dwelling older adults, treatment with atorvastatin demonstrated a 30% relative reduction in major cardiovascular events over roughly six years compared with placebo but did not result ...

Clinicians will increasingly encounter heart rhythm data generated from consumer-grade devices. Consumer-grade smartphone-paired devices and smartwatches have very high sensitivity and specificity for ...

Pulmonary-artery denervation, in addition to guideline-directed medical therapy, resulted in fewer events of clinical worsening than medical therapy alone in patients with pulmonary hypertension ...

In patients with left-sided infective endocarditis a clinical response-tailored antibiotic strategy shortened antibiotic duration by two weeks compared with standard therapy, with no major safety ...

In patients with atrial fibrillation (AFib) at intermediate risk for stroke, DOAC therapy resulted in a lower risk of stroke, systemic embolism, major bleeding or death from cardiovascular causes at ...

Among patients with severe left ventricular (LV) dysfunction and severe coronary heart disease undergoing complex PCI, elective LV unloading with a microaxial flow pump did not reduce the risk of ...

Device-based left atrial appendage (LAA) closure was comparable to non-vitamin K antagonist oral anticoagulant (NOAC) therapy in reducing the combined rate of death from cardiovascular causes, stroke, ...

Pacibekitug, a novel, long-acting monoclonal antibody that targets interleukin-6, produced sustained reductions in inflammatory markers in patients with chronic kidney disease (CKD) and at high ...